Zobrazeno 1 - 10
of 1 297
pro vyhledávání: '"Kosoglou, T."'
Autor:
Fourie AM; Janssen Research & Development, LLC, La Jolla, CA, USA. afourie@its.jnj.com., Cheng X; Protagonist Therapeutics, Newark, CA, USA., Chang L; Janssen Research & Development, LLC, La Jolla, CA, USA., Greving C; Janssen Research & Development, LLC, La Jolla, CA, USA., Li X; Janssen Research & Development, LLC, La Jolla, CA, USA., Knight B; Janssen Research & Development, LLC, La Jolla, CA, USA., Polidori D; Janssen Research & Development, LLC, La Jolla, CA, USA., Patrick A; Janssen Research & Development, LLC, Spring House, PA, USA., Bains T; Janssen Research & Development, LLC, Spring House, PA, USA., Steele R; Janssen Research & Development, LLC, Spring House, PA, USA., Allen SJ; Janssen Research & Development, LLC, Spring House, PA, USA., Patch RJ; Janssen Research & Development, LLC, Spring House, PA, USA., Sun C; Janssen Research & Development, LLC, Spring House, PA, USA., Somani S; Janssen Research & Development, LLC, Spring House, PA, USA., Bhandari A; Protagonist Therapeutics, Newark, CA, USA., Liu D; Protagonist Therapeutics, Newark, CA, USA., Huie K; Protagonist Therapeutics, Newark, CA, USA., Li S; Protagonist Therapeutics, Newark, CA, USA., Rodriguez MA; Janssen Research & Development, LLC, La Jolla, CA, USA., Xue X; Janssen Research & Development, LLC, La Jolla, CA, USA., Kannan A; Janssen Research & Development, LLC, La Jolla, CA, USA., Kosoglou T; Janssen Research & Development, LLC, Spring House, PA, USA., Sherlock JP; Janssen Research & Development, LLC, Spring House, PA, USA., Towne J; Janssen Research & Development, LLC, La Jolla, CA, USA., Holland MC; Janssen Research & Development, LLC, Spring House, PA, USA., Modi NB; Protagonist Therapeutics, Newark, CA, USA.
Publikováno v:
Scientific reports [Sci Rep] 2024 Jul 30; Vol. 14 (1), pp. 17515. Date of Electronic Publication: 2024 Jul 30.
Publikováno v:
International Journal of COPD, Vol 2013, Iss default, Pp 107-116 (2013)
Teddy Kosoglou,1 James Hubbell,2 Fengjuan Xuan,3 David L Cutler,1 Alan G Meehan,4 Bhavna Kantesaria,5 Bret A Wittmer6,† 1Clinical Pharmacology, 2Exploratory Drug Metabolism, 3Early Development Statistics, 4Medical Communications, 5Drug Metabolism/P
Externí odkaz:
https://doaj.org/article/7c279676a6d24ee28592201a0838caa1
Autor:
O'Neil B; Wayne State University School of Medicine, Detroit Medical Center, Detroit, Michigan, USA., Ison MG; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Hallouin-Bernard MC; University Hospital of Tours, Tours, France., Nilsson AC; Infectious Disease Research Unit, Department of Translational Medicine, Skåne University Hospital, Malmö, Sweden., Torres A; Servei de Pneumologia Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Biomedical Research Networking Center on Respiratory Diseases, University of Barcelona, Barcelona, Spain., Wilburn JM; Wayne State University School of Medicine, Detroit Medical Center, Detroit, Michigan, USA., van Duijnhoven W; Janssen Pharmaceutica NV, Beerse, Belgium., Van Dromme I; Janssen Pharmaceutica NV, Beerse, Belgium., Anderson D; Janssen Research and Development, LLC, Titusville, New Jersey, USA., Deleu S; Janssen Pharmaceutica NV, Beerse, Belgium., Kosoglou T; Janssen Research and Development, LLC, Titusville, New Jersey, USA., Vingerhoets J; Janssen Pharmaceutica NV, Beerse, Belgium., Rossenu S; Janssen Pharmaceutica NV, Beerse, Belgium., Leopold L; Janssen Research and Development, LLC, Titusville, New Jersey, USA.
Publikováno v:
The Journal of infectious diseases [J Infect Dis] 2022 Aug 12; Vol. 226 (1), pp. 109-118.
Autor:
Lorant Leopold, Lanno R, Robert W. Finberg, Kauffman Rs, Johan Vingerhoets, Roman Fleischhackl, van Duijnhoven W, Kosoglou T, David E. Anderson
Publikováno v:
The Journal of infectious diseases. 219(7)
BACKGROUND Pimodivir, a first-in-class inhibitor of influenza virus polymerase basic protein 2, is being developed for hospitalized and high-risk patients with influenza A. METHODS In this double-blinded phase 2b study, adults with acute uncomplicate
Autor:
Anderson, Matt S.1 matt_anderson@merck.com, Kosoglou, Teddy1, Statkevich, Paul1, Li, Jing1, Rotonda, Jennifer1, Meehan, Alan G.1, Cutler, David L.1
Publikováno v:
Clinical Pharmacology in Drug Development. Feb2018, Vol. 7 Issue 2, p143-150. 8p.
Autor:
Isingizwe, Zitha Redempta1 (AUTHOR) zitha-isingizwe@ouhsc.edu, Sjoelund, Virginie2 (AUTHOR) v.sjoelund@northeastern.edu, Benbrook, Doris Mangiaracina1,3 (AUTHOR) doris-benbrook@ouhsc.edu
Publikováno v:
Cancers. Oct2024, Vol. 16 Issue 20, p3533. 16p.
Autor:
Kinzi, Jonny1 (AUTHOR), Grube, Markus2 (AUTHOR), Seibert, Isabell1 (AUTHOR), Siegmund, Werner2 (AUTHOR), Meyer zu Schwabedissen, Henriette E.1 (AUTHOR) h.meyerzuschwabedissen@unibas.ch
Publikováno v:
CTS: Clinical & Translational Science. Oct2024, Vol. 17 Issue 10, p1-11. 11p.
Autor:
Kulakowski Corá, Renato1,2 (AUTHOR), Prado Paludo, Gabriela1,2 (AUTHOR), Andrade Paes, Jéssica1,2 (AUTHOR), Bunselmeyer Ferreira, Henrique1,2 (AUTHOR) henrique.bunselmeyer@ufrgs.br
Publikováno v:
Scientific Reports. 9/11/2024, Vol. 14 Issue 1, p1-14. 14p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Finberg RW; University of Massachusetts Medical School, Worcester., Lanno R; Merelahe Family Doctors Center, Tallinn, Estonia., Anderson D; Janssen Research and Development, Titusville, New Jersey., Fleischhackl R; Janssen-Cilag, Vienna, Austria., van Duijnhoven W; Statistics and Decision Sciences, Quantitative Sciences., Kauffman RS; Vertex Pharmaceuticals, Boston, Massachusetts., Kosoglou T; Janssen Research and Development, Titusville, New Jersey., Vingerhoets J; Clinical Virology, Janssen Pharmaceutica, Beerse, Belgium., Leopold L; Janssen Research and Development, Titusville, New Jersey.
Publikováno v:
The Journal of infectious diseases [J Infect Dis] 2019 Mar 15; Vol. 219 (7), pp. 1026-1034.